| Literature DB >> 35630453 |
Cristina Veríssimo1, Cristina Toscano2, Teresa Ferreira3, Gabriela Abreu4, Helena Simões1, José Diogo5, Dinah Carvalho6, Felicidade Santiago7, Ana Lima8, Ana Maria Queirós9, Raquel Sabino1,10.
Abstract
Invasive fungal infections (IFI) have significantly increased over the past years due to advances in medical care for the at-risk immunocompromised population. IFI are often difficult to diagnose and manage, and can be associated with substantial morbidity and mortality. This study aims to contribute to understanding the etiology of invasive and subcutaneous fungal infections, their associated risk factors, and to perceive the outcome of patients who developed invasive disease, raising awareness of these infections at a local level but also in a global context. A laboratory surveillance approach was conducted over a seven-year period and included: (i) cases of invasive and subcutaneous fungal infections caused by filamentous/dimorphic fungi, confirmed by either microscopy or positive culture from sterile samples, (ii) cases diagnosed as probable IFI according to the criteria established by EORTC/MSG when duly substantiated. Fourteen Portuguese laboratories were enrolled. Cases included in this study were classified according to the new consensus definitions of invasive fungal diseases (IFD) published in 2020 as follows: proven IFI (N = 31), subcutaneous fungal infection (N = 23). Those proven deep fungal infections (N = 54) totalized 71.1% of the total cases, whereas 28.9% were classified as probable IFI (N = 22). It was possible to identify the etiological fungal agent in 73 cases (96%). Aspergillus was the most frequent genera detected, but endemic dimorphic fungi represented 14.47% (N = 11) of the total cases. Despite the small number of cases, a high diversity of species were involved in deep fungal infections. This fact has implications for clinical and laboratory diagnosis, and on the therapeutic management of these infections, since different species, even within the same genus, can present diverse patterns of susceptibility to antifungals.Entities:
Keywords: fungal epidemiology; invasive fungal infections; subcutaneous fungal infections; surveillance
Year: 2022 PMID: 35630453 PMCID: PMC9145964 DOI: 10.3390/microorganisms10051010
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Overall characterization of the 76 cases included in this study.
| Gender | Age | Positive Microscopy | Positive Culture | Most Common Risk Factors | |
|---|---|---|---|---|---|
| Male (N; %) | Median (Range) | (N; %) | (N; %) | ||
| IFI (N = 53) | 41; 77.3 | 61 (3–84) | 27; 50.9 | 44; 83.0 | Immunosuppression not associated with transplantation or HIV |
| Subcutaneous (N = 23) | 10; 43.5 | 61 (7–90) | 13; 56.5 | 22; 95.6 | Solid organ transplantation and penetrating trauma |
Legend: IFI: invasive fungal infection; SFI: subcutaneous fungal infection.
Characterization of the validated IFI and SFI cases enrolled in the multicentric surveillance program in the period 2013–2020.
| Case No. | Gender | Age | Biological Sample | Microscopy | Culture | Identification of the Etiological Agent | Classification of the Infection | Risk Factors for Fungal Infection | Outcome |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 40 | Blood | Compatible with | Positive |
| Proven IFI | HIV/AIDS; travels to areas with endemic fungi | Patient’s death due to fungal infection |
| 2 | M | 64 | Jugal mucosa and BAL | Compatible with | Positive |
| Proven IFI | Alcoholism; travels to areas with endemic fungi | Partial response to antifungal treatment |
| 3 | F | 52 | Tissue and BAL | Septate hyphae | Positive | Proven IFI | Invasive surgery, imunossupression | Partial response to antifungal treatment | |
| 4 | M | 48 | BAL | Septate hyphae | Positive | Probable IFI | Solid organ transplant; invasive surgery; alcoholism, chronic liver disease | Patient’s death due to fungal infection | |
| 5 | M | 76 | Skin | Yeasts | Positive |
| Proven IFI | HIV/AIDS; travels to areas with endemic fungi | Partial response to antifungal treatment |
| 6 | M | 65 | Skin (both leg/hand) | Septate hyphae | Positive | Proven Subcutaneous | Diabetes mellitus; immunosuppression | Good response to antifungal treatment | |
| 7 | M | 29 | Bone marrow | Yeasts | Positive |
| Proven IFI | HIV/AIDS; travels to areas with endemic fungi | Patient’s death due to fungal infection |
| 8 | M | 77 | BAL | NP | Positive | Probable IFI | Immunosuppression; intensive care hospitalization | NA | |
| 9 | M | 56 | Brain abcess | NA | Positive |
| Proven IFI | Alcoholism, drug abuse, chronic liver disease | Improvement |
| 10 | M | 7 | Skin | Septate hyphae | Positive |
| Proven Subcutaneous | Trauma | Partial response to antifungal treatment |
| 11 | M | 56 | Pleural fluid | Aseptate hyphae | Positive |
| Probable IFI | Trauma, alcoholism | NA |
| 12 | F | 47 | Skin | Fungal elements | Positive | Proven Subcutaneous | NA | NA | |
| 13 | M | 64 | Colon | Yeasts | Positive |
| Proven IFI | Alcoholism, travels to areas with endemic fungi | NA |
| 14 | M | 3 | Sputum/urine | NP | Positive |
| Probable IFI | Intensive care hospitalization; invasive surgery; early birth | Good response to antifungal treatment |
| 15 | M | 67 | BAL | Negative | Positive | Probable IFI | COPD | NA | |
| 16 | M | 29 | Skin | Negative | Positive |
| Proven Subcutaneous | Trauma (cattle breeder) | Good response to antifungal treatment |
| 17 | M | 68 | Tonsil | Yeasts | Positive |
| Proven IFI | Alcoholism; travels to areas with endemic fungi | Good response to antifungal treatment |
| 18 | F | 59 | Skin | Septate hyphae | Positive |
| Proven Subcutaneous | Solid organ transplant | NA |
| 19 | M | 81 | Skin | Yeasts | Positive |
| Proven Subcutaneous | NA | NA |
| 20 | F | 75 | Skin | NP | Positive | Proven Subcutaneous | Imunossupression | Good response to antifungal treatment | |
| 21 | F | 61 | Skin | Compatible with | Positive |
| Proven Subcutaneous | NA | NA |
| 22 | M | 90 | Skin | Septate hyphae | Positive | Proven Subcutaneous | Immunosuppression (lung cancer) | NA | |
| 23 | M | 29 | BAL/Thraqueal lesion | Septate hyphae | Positive |
| Probable IFI | HIV/AIDS; travels to areas with endemic fungi | NA |
| 24 | F | 42 | BAL | NP | Positive | Probable IFI | Solid organ transplant, COPD | NA | |
| 25 | M | 72 | Skin | Large yeasts | Negative |
| Proven IFI | Chronic kidney disease; travel to areas with endemic fungi; immunossupression | NA |
| 26 | M | 51 | BAL | NA | Positive |
| Probable IFI | Organ transplant; HIV/AIDS | NA |
| 27 | M | 86 | Sphenoid bone | NA | Positive | Proven IFI | NA | NA | |
| 28 | F | 78 | BAL | NA | Positive | Probable IFI | Invasive surgery | Patient’s death due to fungal infection | |
| 29 | M | 14 | Nasal tissue | NP | Negative |
| Probable IFI | Bone marrow transplant | Good response to antifungal treatment |
| 30 | F | 75 | Skin | septate hyphae | Positive |
| Proven Subcutaneous | Penetrating trauma | NA |
| 31 | F | 63 | Skin | NP | Positive |
| Proven Subcutaneous | Imunossupression | NA |
| 32 | M | 47 | Lip tissue | Compatible with | Negative |
| Proven IFI | Alcoholism; travels to areas with endemic fungi | Good response to antifungal treatment |
| 33 | M | 74 | Skin | NP | Positive | Proven Subcutaneous | Chemotherapy; invasive surgery | Relapse | |
| 34 | M | 68 | Sphenoid bone | Aseptate hyphae | Positive |
| Proven IFI | Diabetes mellitus | Patient’s death due to fungal infection |
| 35 | F | 80 | Skin | NP | Positive |
| Proven Subcutaneous | Penetrating trauma | NA |
| 36 | M | 61 | Eye tissue | Aseptate hyphae | NP | Not identified Mucorales | Proven IFI | Invasive surgery (eye) | NA |
| 37 | F | 55 | BAL | NP | Positive |
| Proven IFI | Solid organ transplant | NA |
| 38 | F | 79 | Skin | NA | Positive |
| Proven Subcutaneous | Chemotherapy | NA |
| 39 | M | 54 | Bone | NP | Positive |
| Proven Subcutaneous | Invasive surgery | NA |
| 40 | F | 48 | Finger | NP | Positive | Proven Subcutaneous | NA | NA | |
| 41 | F | 51 | Blood culture | NP | Positive |
| Proven IFI | NA | NA |
| 42 | M | 64 | Bronchial aspirate | NP | Positive | Probable IFI | Imunossupression | NA | |
| 43 | M | 53 | BAL | NP | Positive |
| Probable IFI | HIV/AIDS | NA |
| 44 | M | 69 | Periorbital exsudate | NP | Positive | Not identified Mucorales | Probable IFI | Diabetes mellitus | Patient’s death due to fungal infection |
| 45 | M | 65 | Brain abcess | Septate hyphae | Positive | Proven IFI | Diabetes mellitus | Patient’s death due to fungal infection | |
| 46 | F | 40 | Nasal exsudate | NP | Positive |
| Probable IFI | Imunossupression (acute myeloid leukemia) | NA |
| 47 | M | 52 | Stump tissue (traumatic amputation) | NP | Positive |
| Proven IFI | Traumatic amputation | NA |
| 48 | M | 64 | BAL (but with multiple site isolates) | NP | Positive | Proven IFI | Intensive care hospitalization | No response to antifungal treatment | |
| 49 | M | 83 | BAL | NP | Positive |
| Probable | Imunossupression | NA |
| 50 | F | 61 | Skin | Negative | Positive |
| Proven Subcutaneous | Solid organ transplant | NA |
| 51 | F | 26 | Skin | Septate hyphae | Positive | Proven IFI | Imunossupression (acute myeloid leukemia) | NA | |
| 52 | M | 67 | Lung tissue | Compatible with | NP |
| Proven IFI | Travels to areas of endemic fungi; intensive smoker | NA |
| 53 | M | 75 | Thyroid aspirate | Septate hyphae | Negative | Negative | Proven IFI | NA | NA |
| 54 | F | 75 | BAL | NP | Positive |
| Probable IFI | Imunossupression | NA |
| 55 | M | 76 | Blood culture | NA | Positive |
| Proven IFI | Acute myeloid leukemia | NA |
| 56 | F | 58 | Skin | NA | Positive |
| Proven Subcutaneous | Solid organ transplant | NA |
| 57 | M | 63 | Brain tissue | NA | Positive | Proven IFI | NA | NA | |
| 58 | M | 56 | Skin | Septate hyphae | Positive | Proven Subcutaneous | NA | NA | |
| 59 | M | 65 | Blood | NP | Positive |
| Proven IFI | Intensive care hospitalization | NA |
| 60 | M | 61 | Cornea scraping tissue | NA | Positive |
| Probable IFI | NA | NA |
| 61 | M | 55 | BAL | NA | Positive |
| Probable IFI | Intensive care hospitalization; mechanic ventilation | Partial response to antifungal treatment |
| 62 | F | 60 | Skin | Septate hyphae | Positive |
| Proven Subcutaneous | Solid organ transplant | NA |
| 63 | F | 66 | Bone biopsy/abcess | NP | Positive | Proven IFI | Hemato-oncological patient | NA | |
| 64 | M | 56 | Liver tissue | Aseptate hyphae | Negative | Not identified Mucorales | Proven IFI | NA | NA |
| 65 | M | 58 | Skin | Septate hyphae | Positive |
| Proven Subcutaneous | Solid organ transplant | NA |
| 66 | M | 63 | Skin | Fungal elements | Negative |
| Proven Subcutaneous | NA | NA |
| 67 | M | 37 | Pleural fluid | NP | Positive |
| Probable IFI | Imunossupression (sarcoidosis) | NA |
| 68 | M | 67 | Skin | Septate hyphae | Positive |
| Probable IFI | Solid organ transplant | NA |
| 69 | M | 64 | Nasal sinus tissue | Septate hyphae | Positive |
| Proven IFI | NA | NA |
| 70 | M | 52 | Bone marrow | Intracellular yeasts | Negative |
| Proven IFI | HIV/AIDS; travels to areas with endemic fungi | Patient’s death due to fungal infection |
| 71 | F | 33 | Nasal sinus tissue | NP | Positive |
| Probable IFI | Imunossupression (severe aplastic anemia) | NA |
| 72 | F | 56 | Skin | Septate hyphae | Positive |
| Proven Subcutaneous | Solid organ transplant (liver); diabetes mellitus | No response to antifungal treatment |
| 73 | M | 56 | Tissue (source not referred) | Septate hyphae | Positive |
| Proven IFI | HIV/AIDS | NA |
| 74 | M | 43 | Lung tissue | Septate hyphae | Negative |
| Proven IFI | NA | NA |
| 75 | F | 84 | BAL/sputum | Septate hyphae | Positive | Probable IFI | Imunossupression; diabetes mellitus | NA | |
| 76 | F | 40 | Cervical abscess | Large yeasts | Positive |
| Proven IFI | HIV/AIDS; travels to areas with endemic fungi | NA |
Legend: NP: not performed; NA: information not available; COPD: chronic pulmonary obstructive disease; HIV: human immunodeficiency virus; AIDS: acquired immunodeficiency syndrome; BAL: Bronchoalveolar lavage; IFI: invasive fungal infection; SFI: subcutaneous fungal infection.